Publicaciones en las que colabora con José Luis Vicario Moreno (10)

2024

  1. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210)

    Cytotherapy, Vol. 26, Núm. 1, pp. 25-35

2023

  1. Rationale for combined therapies in severe-to-critical COVID-19 patients

    Frontiers in Immunology, Vol. 14

2022

  1. Identifying SARS-CoV-2 ‘memory’ NK cells from COVID-19 convalescent donors for adoptive cell therapy

    Immunology, Vol. 165, Núm. 2, pp. 234-249

2021

  1. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

    Trials, Vol. 22, Núm. 1

  2. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)

    EClinicalMedicine, Vol. 39

2018

  1. Characterization of the novel HLA-A*80:04 allele identified in a Spanish volunteer donor

    HLA, Vol. 92, Núm. 4, pp. 245-246

2016

  1. Genomic full-length sequence of two new HLA-C alleles, HLA-C*04:239 and HLA-C*05:137

    HLA

  2. Genomic sequence of HLA-B*41:43, a new HLA-B allele generated by an intralocus recombination mechanism

    HLA, Vol. 87, Núm. 2, pp. 111-113

  3. The new HLA-A*24:321 shows one conservative amino acid replacement compared with HLA-A*24:02:01

    HLA, Vol. 87, Núm. 1, pp. 50-51

2015

  1. A new HLA-B allele, B*49:34, sequenced in a Spanish individual

    Tissue Antigens, Vol. 85, Núm. 4, pp. 293-294